Total | Determinate | Indeterminate | Univariate | Multivariate | ||
OR (95% CI) | p-value | p-value | ||||
Categorical variables: controls | ||||||
Female | 62; 60 (50–69) | 61; 98 (95–100) | 1; 1.6 (0–7.3) | 0 | >0.05 | >0.05 |
Male | 42; 40 (31–50) | 42; 100 (98–100) | (0–6.7) | |||
Categorical variables: patients | ||||||
Male | 258; 58 (53–62) | 226; 88 (84–92) | 26; 10 (6.4–14) | 0.6 (0.4–0.9): male | <0.05 | >0.05 |
Female | 189; 42 (38–47) | 157; 83 (78–88) | 32; 17 (12–23) | |||
Disease group | ||||||
Organ transplant | 233; 52 (48–57) | 216; 93 (89–96) | 17; 7.3 (4–11) | 0.4 (0.2–0.8) | <0.05 | |
Male | 157; 67 (61–72) | 147; 94 (88–97) | 10; 6.4 (3–11) | |||
Female | 76; 33 (27–39) | 69; 90 (82–96) | 7; 9.8 (4–18) | |||
Autoimmune diseases | 76; 18 (14–22) | 60; 79 (70–88) | 16; 21 (12–30) | 2.6 (1.4–5.0) | <0.05 | 0.073 |
Male | 22; 29 (20–40) | 22; 100 | 0; 0 | |||
Female | 54; 71 (60–80) | 38; 70 (57–80) | 16; 30 (19–43) | |||
Primary immunodeficiency | 45; 10.1 (7.3–13) | 41; 91 (83–99) | 4; 9 (1–18) | 0.8 (0.3–2.3) | >0.05 | |
Male | 21; 47 (32–60) | 20; 96 (76–100) | 1; 4.2 (0–24) | |||
Female | 24; 53 (39–67) | 21; 87 (68–96) | 3; 13 (3–31) | |||
Stem cell transplant | 42; 9.4 (6.7–12) | 23; 55 (40–70) | 19; 45 (30–60) | 8.1 (3.0–22) | <0.05 | <0.05 |
Male | 25; 60 (44–73) | 11; 44 (27–63) | 14; 56 (37–73) | |||
Female | 17; 40 (27–56) | 12; 70 (47–87) | 5; 30 (13–53) | |||
HIV patients | 51; 11.4 (8.5–14) | 49; 96 (91–100) | 2; 3.9 (0–10) | 2.3 (1.5–4.2) | <0.05 | |
Male | 33; 65 (51–76) | 32; 97 (83–100) | 1; 3 (0–17) | |||
Female | 18; 35 (24–49) | 17; 94 (72–100) | 1; 6 (0–28) | |||
Medication | ||||||
Steroids | 230; 51 (47–56) | 195; 85 (80–89) | 35; 15.2 (11–20) | >0.05 | >0.05 | |
Cyclosporin | 147; 33 (29–37) | 127; 86 (81–92) | 20; 13.6 (8–19) | >0.05 | >0.05 | |
Tacrolimus | 95; 21 (17–25) | 85; 90 (84–96) | 10; 10.5 (4–17) | >0.05 | >0.05 | |
Methotrexate | 25; 6 (4–8) | 22; 88 (75–100) | 3; 12 (0–25) | >0.05 | >0.05 | |
Mycophenolate | 173; 39 (34–43) | 158; 91 (87–96) | 15; 8.7 (4–13) | 0.8 (0.7–1.0) | <0.05 | >0.05 |
Risk factors | ||||||
Diabetes | 31; 7 (5–10) | 28; 90 (80–100) | 3; 9.7 (0–20) | >0.05 | >0.05 | |
Smoking | 28; 6 (4–9) | 26; 93 (83–100) | 2; 7.1 (0–17) | >0.05 | >0.05 | |
Having had dialysis | 206; 46 (42–51) | 190; 92 (89–96) | 16; 7.8 (4–11) | >0.05 | >0.05 | |
Continuos variables: patients | ||||||
Age yrs | 447; 52.4±13.8 | 389; 52.1±13.7 | 58; 53.8±14.2 | >0.05 | >0.05 | |
Erythrocyte count 106·μL−1 | 431; 4.4±0.7 | 374; 4.5±0.7 | 57; 3.9±0.7 | <0.05 | <0.05 | |
Leukocyte count 1000·μL−1 | 435; 6.9±3.4 | 378; 7±3.4 | 57; 6.4±3.4 | >0.05 | >0.05 | |
Lymphocyte count μL | 305; 1614±836 | 266; 1691±817 | 39; 1085±771 | <0.05 | <0.05 | |
CD3 count μL−1 | 64; 1114±637 | 56; 1205±614 | 8; 481±421 | <0.05 | <0.05 | |
CD4 count μL−1 | 78; 462±300 | 68; 483±289 | 10; 313±350 | >0.05 | >0.05 | |
CD8 count μL−1 | 74; 585±452 | 64; 656±446 | 10; 134±90 | <0.05 | <0.05 | |
Length of dialysis months | 196; 56±44 | 182; 55.1±43 | 14; 68.5±46 | >0.05 | >0.05 | |
Length of illness months | 413; 91±90 | 360; 94±88 | 53; 78±102 | >0.05 | >0.05 |
Data are presented as n; % (95% confidence interval) or n; mean±sd, unless otherwise stated. Significant differences in univariate and multivariate analysis are shown in bold. QuantiFERON®–TB Gold in tube is manufactured by Cellestis, Carnegie, Australia.